Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.
Ravindra Uppaluri, MD, PhD,
Ravindra Uppaluri, MD, PhD, is the chief of head and neck surgery at the Dana-Farber Brigham Cancer Center, and chief of the otolaryngology group at the Brigham and Women's Hospital.
Articles by Ravindra Uppaluri, MD, PhD,
Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.
Latest Updated Articles
FDA OKs Perioperative Pembrolizumab in HNSCC: Findings From KEYNOTE-689Published: June 15th 2025 | Updated:
- KEYNOTE-689 Leads to FDA Approval of Perioperative Pembrolizumab in HNSCC
Published: June 14th 2025 | Updated: